These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1980453)

  • 21. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus.
    Graham JP; Stam D
    Pharm Pract Manag Q; 1997 Oct; 17(3):1-9. PubMed ID: 10173306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-insulin-dependent diabetes mellitus: a clinical strategy.
    Skyler JS
    Diabetes Care; 1984; 7 Suppl 1():118-29. PubMed ID: 6376024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of insulin therapy on body fat distribution in NIDDM patients with secondary sulfonylurea failure: a preliminary report.
    Takei I; Takayama S; Yamauchi A; Nakamoto S; Kitamura Y; Katsukawa F; Yamazaki H; Saruta T; Inoue S
    Eur J Clin Nutr; 1998 Feb; 52(2):153-4. PubMed ID: 9505163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for the association of sulfonylurea and insulin.
    Del Prato S
    Am J Med; 1991 Jun; 90(6A):77S-82S. PubMed ID: 1872309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man.
    Pfeifer MA; Halter JB; Judzewitsch RG; Beard JC; Best JD; Ward WK; Porte D
    Diabetes Care; 1984; 7 Suppl 1():25-34. PubMed ID: 6376026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
    Rosenkranz B
    Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Will sulfonylurea treatment of impaired glucose tolerance delay development and complications of NIDDM?
    Melander A; Bitzén PO; Sartor G; Scherstén B; Wåhlin-Boll E
    Diabetes Care; 1990 Aug; 13 Suppl 3():53-8. PubMed ID: 2209345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfonylureas in NIDDM.
    Groop LC
    Diabetes Care; 1992 Jun; 15(6):737-54. PubMed ID: 1600834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug therapy in subjects with impaired glucose tolerance].
    Kawamori R; Yoshii H
    Nihon Rinsho; 1996 Oct; 54(10):2750-3. PubMed ID: 8914439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulfonylureas.
    Zimmerman BR
    Endocrinol Metab Clin North Am; 1997 Sep; 26(3):511-22. PubMed ID: 9314012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin treatment in elderly patients with non-insulin-dependent diabetes mellitus. A double-edged sword?
    Niskanen L
    Drugs Aging; 1996 Mar; 8(3):183-92. PubMed ID: 8720744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
    Goo AK; Carson DS; Bjelajac A
    J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study.
    Vestergaard H; Weinreb JE; Rosen AS; Bjørbaek C; Hansen L; Pedersen O; Kahn BB
    J Clin Endocrinol Metab; 1995 Jan; 80(1):270-5. PubMed ID: 7829624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus.
    Glauber HS; Henry RR; Wallace P; Frank BH; Galloway JA; Cohen RM; Olefsky JM
    N Engl J Med; 1987 Feb; 316(8):443-9. PubMed ID: 3543679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus.
    Beck-Nielsen H; Hjøllund E; Pedersen O; Richelsen B; Sørensen NS
    Diabetes Care; 1984; 7 Suppl 1():100-5. PubMed ID: 6428842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin use in NIDDM. Rationale based on pathophysiology of disease.
    Turner RC; Holman RR
    Diabetes Care; 1990 Sep; 13(9):1011-20. PubMed ID: 2226108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies for insulin therapy in type 2 diabetes.
    Edelman SV; Morello CM
    South Med J; 2005 Mar; 98(3):363-71. PubMed ID: 15813164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.